A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy in Patients With Inoperable, Locally-advanced (Stage III) NSCLC.

Trial Profile

A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy in Patients With Inoperable, Locally-advanced (Stage III) NSCLC.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2012

At a glance

  • Drugs Carboplatin; Cisplatin; Paclitaxel; Radretumab; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Planned End Date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 15 Oct 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top